Skip to main content
Premium Trial:

Request an Annual Quote

Windfall from CombiMatrix Settlement Turbo-charges Nanogen s Q4 Revenue

NEW YORK, Feb. 6 - Nanogen today reported a surge in fourth-quarter revenues atop a slight increase in R&D spending and strong net income. However, most of the revenue and earnings were the result of a windfall from a legal settlement in October.

 

For the period ended Dec. 31, Nanogen reported $12.1 million in revenue, up from $2.3 million one year ago. The company said, however, that receipts from sponsored research fell to $375,000 from $1.2 million year over year. Similarly, sales in the quarter fell to $511,000 from $691,000, Nanogen said.

 

There were two bright spots in the quarter: contracts and grants increased to $414,000 from $376,000 year over year, and CombiMatrix handed over $10.8 million as part of its defeat in a patent-infringement lawsuit.

 

Fourth-quarter R&D spending at Nanogen, meantime, increased to $5.3 million from $4.5 million one year ago. Consequently, the company posted a net income of $2 million, or $.09 per share, compared with a net loss of $7.5 million, or $.35 per share, in the fourth quarter 2001.

 

Nanogen said it had roughly $53 million in cash, cash equivalents, and short-term investments as of Dec. 31.

The Scan

Steps for Quick Review

The US Food and Drug Administration is preparing for the quick review of drugs and vaccines for the Omicron variant, according to the Wall Street Journal.

Moving Away From Using Term 'Race'

A new analysis finds that geneticists are using the term "race" in their papers less than in years past, as Science reports.

Point of the Program

The Guardian writes that some scientists have called the design of a UK newborn sequencing program into question.

Science Papers Present Multi-Omic Analysis of Lung Cells, Regulation of Cardiomyocyte Proliferation

In Science this week: a multi-omic analysis of lung cells focuses on RIT1-regulated pathways, and more.